| Issue | Title | |
| Vol 2014, No 6 (2014) | Abbott Targets Growth in Emerging Markets with CFR Pharmaceuticals Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 44 (2004) | Abbott to Acquire Diagnostics Manufacturer for US$392 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 5 (2012) | Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 6 (2011) | Abbott to Develop and Commercialise Biotest’s BT-061 for Autoimmune Diseases | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 27 (2002) | Abbott to Distribute Cholestech Glucose Monitoring System | Abstract |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | Abbott to take full control of Hokuriku Seiyaku | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 6 (2009) | Abbott’s Cholesterol Drug Deal with AstraZeneca | Abstract |
| Taskin Ahmed | ||
| Vol 2024, No 11 (2024) | AbbVie Acquires Aliada Therapeutics for US$1.4 B to Advance Alzheimer’s Research | Abstract pdf html |
| Swati Sharan | ||
| Vol 2019, No 7 (2019) | AbbVie Acquires Allergan for US$63 B to Ease Humira Fears | Abstract pdf |
| Michelle Liu | ||
| Vol 2025, No 7 (2025) | AbbVie Acquires Capstan Therapeutics and its CART-T Therapy CPTX2309 for US$2.1 B | Abstract pdf html |
| Swati Sharan | ||
| Vol 2024, No 7 (2024) | AbbVie Acquires Celsius Therapeutics and its IBD Portfolio for US$250 M | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2016, No 3 (2016) | AbbVie adds Boehringer Ingelheim’s BI 655066 to its Autoimmune Portfolio | Abstract pdf html |
| Natasha Berry | ||
| Vol 2018, No 7 (2018) | AbbVie Adds Depth to Pipeline With Calico And Calibr Deals | Abstract pdf html |
| Subham Nandi | ||
| Vol 2022, No 8 (2022) | AbbVie Collaborates with Sosei Heptares to Develop Small Molecules for Neurological Conditions | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2025, No 2 (2025) | AbbVie Collaborates with Xilio Therapeutics to Develop Antibody-Based Immunotherapies | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2020, No 6 (2020) | AbbVie Commits US$750 M Upfront to Oncology Collaboration with Genmab | Abstract pdf html |
| Michelle Liu | ||
| Vol 2025, No 3 (2025) | AbbVie Enters Obesity Space Through US$2.2 B Licensing Pact with Gubra | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2019, No 3 (2019) | AbbVie Enters Second Vectorised Antibody Partnership with Voyager Therapeutics | Abstract html pdf |
| Michelle Liu | ||
| Vol 2022, No 12 (2022) | AbbVie Forms Auto-Immunology Partnership with HotSpot Therapeutics for US$335M | Abstract pdf html |
| Swati Sharan | ||
| Vol 2015, No 3 (2015) | AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 3 (2018) | AbbVie Investigates One-Dose Therapy for Alzheimer’s with Voyager Therapeutics Collaboration | Abstract pdf html |
| Natasha Piper | ||
| Vol 2019, No 2 (2019) | AbbVie Joins BCMA Race with Tenebio in a US$90 M Upfront Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2013, No 4 (2013) | AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 1 (2023) | AbbVie Partners with Immunome and Anima in Oncology-Focused Deals | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2014, No 10 (2014) | AbbVie Partners with Infinity and Google-Backed Calico in Dealmaking Spree | Abstract |
| Heather Cartwright | ||
| Vol 2025, No 2 (2025) | AbbVie Signs Immuno-Oncology Partnership with Neomorph for US$1.64 B | Abstract pdf html |
| Swati Sharan | ||
| Vol 2025, No 8 (2025) | AbbVie Signs US$1.225 B Licensing Pact with IGI Therapeutics for Oncology and Autoimmune Disease Treatment | Abstract pdf html |
| Naini Anand | ||
| Vol 2024, No 6 (2024) | AbbVie Signs US$1.7 B Pact with FutureGen for IBD Drug | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2025, No 9 (2025) | AbbVie to Acquire Gilgamesh’s Psychedelic Depression Treatment for US$1.2 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 12 (2023) | AbbVie to Acquire ImmunoGen for US$10.1 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 12 (2023) | AbbVie to Buy Cerevel Therapeutics for US$8.7 B to Bolster Neuroscience Portfolio | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2016, No 5 (2016) | AbbVie’s Deal Spree Enriches its Pipeline with Oncology Assets | Abstract pdf html |
| Taskin Ahmed & Jasmine Kalsi | ||
| Vol 2013, No 10 (2013) | Ablynx Advances Ambitions by Partnering with AbbVie and Merck Serono | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 2 (2014) | Ablynx and Merck & Co. Expand Alliance with US$2.3 B Cancer Immunotherapy Discovery Deal | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 10 (2012) | Ablynx and Merck & Co. Partner to Develop Nanobody® Ion Channel Modulators | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 11 (2011) | Ablynx and Merck Serono Form Third Nanobody® Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 100 (2008) | Ablynx’s Nanobodies® Take in Another Big Pharma | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2022, No 10 (2022) | Abpro Signs US$1.75 B Collaboration Deal with Celltrion | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2006, No 72 (2006) | Abraxis and AstraZeneca Exchange Agreements | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 84 (2007) | Academia’s Cash Cow: Royalty Streams | Abstract |
| Business Review Editor | ||
| Vol 2020, No 10 (2020) | Acadia Buys Pain Management Specialist CerSci Therapeutics for US$940 M | Abstract pdf html |
| Ashish Tripathi & Michelle Liu | ||
| Vol 2003, No 40 (2003) | Acambis plc | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 8 (2011) | Acceleron Pharma and Celgene Collaborate Again in Anaemia | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 93 (2008) | Acceleron Signs Deals for Bone-Forming Compounds | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | Access Oncology Licenses Zentaris’ Anticancer Compound | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 98 (2008) | Access Pharmaceuticals Boosts Product Pipeline Through Acquisition of MacroChem | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2015, No 6 (2015) | Achillion Disappoints Investors by Partnering HCV Assets with Janssen | Abstract |
| Heather Cartwright & Shruti Desai | ||
| Vol 2016, No 3 (2016) | Acorda Boosts Parkinson’s Disease Franchise with US$363 M Acquisition of Biotie | Abstract pdf html |
| Heather Cartwright & Sayani Datta | ||
| Vol 2021, No 10 (2021) | Acquisition of Antibody Specialist Teneobio for US$2.5 B by Amgen | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2006, No 75 (2006) | Acquisitions with a Twist | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 1 (2019) | Acrotech Biopharma to Enhance US Presence with Spectrum Pharmaceuticals | Abstract pdf html |
| Michelle Liu | ||
| Vol 2007, No 79 (2007) | Actavis Acquires Abrika and ZiO Zdorovje | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 5 (2013) | Actavis Agrees US$8.5 B Buyout of Warner Chilcott to Expand Speciality Drug Portfolio | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 2 (2013) | Actavis Expands in Women’s Health with Uteron Pharma Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | Actelion Acquires Option to Buy CNS Drug Developer Trophos | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 3 (2012) | Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 45 (2004) | Actelion Ltd | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 27 (2002) | Actelion to Market Zavesca in Europe | Abstract |
| Business Review Editor | ||
| Vol 2023, No 3 (2023) | Adaptimmune and TCR2 Merge to Form a Solid Tumour Company | Abstract pdf html |
| Shweta Gupta & Lucy Haggerty | ||
| Vol 2002, No 29 (2002) | Adherex Technologies to Merge with Oxiquant | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 63 (2005) | Adherex Transformed by Deal with GSK | Abstract |
| Business Review Editor | ||
| Vol 2013, No 8 (2013) | Adimab Strikes its First Technology Transfer Deals with GSK and Biogen Idec | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 91 (2008) | Adolor and Pfizer Collaborate on Delta Opioid Agonists | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 28 (2002) | Adolor to License Key Technology from Eli Lilly | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 86 (2007) | Advanced Medical Optics Proposes Acquisition of Bausch & Lomb | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 2 (2011) | AdventRx Acquires SynthRx for Late-Stage Sickle Cell Disease Drug | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 85 (2007) | Adverse effect | Details jpg |
| Business Review Editor | ||
| Vol 2007, No 81 (2007) | Advexin (adenoviral p53) | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 9 (2018) | Affimed Enters into US$5 B Cancer Immunotherapy Collaboration with Genentech | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 69 (2006) | Affymax and Takeda to Commercialize Hematide™ | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 51 (2004) | Agensys and Genentech in Cancer Antibody Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 65 (2005) | Agensys Fuels Merck & Co.'s Cancer Ambitions | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 5 (2012) | Agilent Technologies Agrees to Acquire Dako for US$2.2 B in its Largest Deal to Date | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 8 (2023) | Agios signs US$147.5 M License Deal with Alnylam’s RNAi therapeutic for Polycythemia Vera | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2005, No 55 (2005) | Agis Puts an End to Merger Rumours | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 6 (2009) | Agreement Between Roche and Tekmira to Advance RNAi Product Candidates | Abstract |
| Taskin Ahmed | ||
| Vol 2013, No 4 (2013) | Ajinomoto Expands Biologics Development and Manufacturing Capabilities with Althea Technologies Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 1 (2017) | Akebia and Otsuka partner for vadadustat with a deal worth over US$1 B | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2017, No 3 (2017) | Akebia Broadens its Pipeline by Licensing J&J’s HIF-Based Portfolio | Abstract html pdf |
| Jawala Prasad | ||
| Vol 2021, No 6 (2021) | Akebia Expands Renal Disease Portfolio with Cyclerion’s Praliciguat | Abstract pdf html |
| Sasha Yachu & Michelle Liu | ||
| Vol 2010, No 1 (2010) | Alcon Buys Ophthalmology Assets from Sirion | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 9 (2009) | Alcon Enters Biologicals Arena | Abstract |
| Taskin Ahmed | ||
| Vol 2022, No 8 (2022) | Alcon to Acquire Aerie Pharmaceuticals for US$770 M | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 11 (2009) | Alder Signs Billion Dollar Deal with Bristol-Myers Squibb | Abstract |
| Taskin Ahmed | ||
| Vol 2020, No 5 (2020) | Alexion Acquires Portola for US$1.44 B | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 10 (2019) | Alexion Continues to Diversify its Portfolio with Achillion Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2012, No 2 (2012) | Alexion Gains First Potential Drug for Hypophosphatasia via US$1.08 B Enobia Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 2 (2011) | Alexion Pharmaceuticals Boosts its Rare Disease Pipeline with Taligen Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 2 (2019) | Alexion Pharmaceuticals Takes on Amyloidosis with Caelum Biosciences | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 9 (2018) | Alexion to Acquire Antibody Specialist Syntimmune for US$1.2 B | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 4 (2018) | Alexion to Acquire Rare Disease Specialist Wilson Therapeutics | Abstract pdf html |
| Natasha Piper | ||
| Vol 2015, No 5 (2015) | Alexion to Acquire Synageva for US$8.4 B to Diversify its Rare Disease Portfolio | Abstract |
| Heather Cartwright & Tridisha Goswami | ||
| Vol 2012, No 10 (2012) | Alfa Wassermann Partners with Theravance to Develop Velusetrag for Gastroparesis | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 10 (2023) | Alfasigma to Acquire Intercept Pharmaceuticals to Expand into Liver Diseases | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2005, No 64 (2005) | ALK-Abello AS | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 11 (2019) | Alkermes Signs US$950 M Deal with Rodin Therapeutics to Boost CNS Pipeline | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 5 (2011) | Alkermes to Purchase Elan’s Drug Delivery Unit for US$960 M in Cash and Stock | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 62 (2005) | Alkermes, Cephalon and Vivitrex#174;: Pioneering the Alcohol Dependence Market | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 9 (2016) | Allergan Acquires Vitae Pharmaceuticals to Strengthen Its Dermatology Portfolio | Abstract pdf html |
| Keshav Mahawar | ||
| Vol 2011, No 7 (2011) | Allergan Agrees to Acquire Vicept Therapeutics in US$275 M Deal | Abstract |
| Heather Cartwright | ||
| 301 - 400 of 2613 Items | << < 1 2 3 4 5 6 7 8 9 10 > >> | |